CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB - News) today announced that it has elected to participate with Genentech (NYSE: DNA - News) in the development and commercialization of GA101 in the United States. Genentech recently acquired development and U.S. commercialization rights to GA101 from Glycart, a company owned by Roche, and Roche. GA101 is a novel humanized anti-CD20 monoclonal...

ALLSCHWIL, Switzerland--(BUSINESS WIRE)--Polyphor Ltd today announced that it has entered into an exclusive worldwide discovery and license agreement with Allergan, Inc., under which Allergan obtains the rights to develop PEM cytokine inhibitors for the treatment of conditions and diseases of the eye.

Under the agreement, Allergan and Polyphor will conduct a research program designed to identify...

GOETTINGEN, Germany, Oct 31, 2008 (BUSINESS WIRE) -- Sartorius Stedim Biotech GmbH (SSB) (Paris:DIM), a group subsidiary of the biotechnology supplier Sartorius Stedim Biotech, signed an agreement to acquire the Swiss-based technology company Wave Biotech AG. Both companies have already been closely working together since 2006. In addition to their joint research projects, Sartorius Stedim Biotech...

Chippenham, UK 31 October 2008: Vectura Group plc (Vectura; LSE: VEC) today announces that a 7.5 million (6 million) milestone payment will be received from the leading pharmaceutical company, Boehringer Ingelheim GmbH (Boehringer Ingelheim), under the worldwide collaboration, development and licence agreement with Vectura.

Under the terms of the non-exclusive agreement...

TOKYO, Oct 31 (Reuters) - Japanese drugmaker Daiichi Sankyo Co Ltd said on Friday it would advance its DU-176b clot prevention drug to Phase III trials, the final stage before marketing approval, in November.

NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL - News) and Bristol-Myers Squibb Company (NYSE: BMY - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the companies supplemental Biologics License Application (sBLA) to broaden the indication for ERBITUX (cetuximab) to include use in combination with platinum-based chemotherapy...

DUBLIN, IRELAND--(MARKET WIRE)--Oct 31, 2008 -- Trinity Biotech plc (NasdaqGS:TRIB - News), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2008.

Quarter 3 Results

Revenues for quarter 3, 2008 amounted to US$35.6m compared to US$33.7m for the same period...

ST. LOUIS, Oct. 30 /PRNewswire-FirstCall/ -- Sigma-Aldrich is pleased to announce the appointment of Rakesh Sachdev as Vice President and Chief Financial Officer (CFO) along with other organization changes that are designed to deepen the bench strength of its management team and enable the implementation of its initiatives to drive growth at above market rates in 2009-2011.

President and...

LONDON - Pharmaceutical company AstraZeneca PLC posted a 29 percent rise in third quarter net profit on Thursday as strong sales in emerging markets like China helped offset flat demand for its products in the United States.

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated today reported strong financial results for the third quarter of 2008 and raised its full-year guidance for earnings per share (EPS).

"Gen-Probe posted very good financial results in the third quarter of 2008, driven by solid growth in both our clinical diagnostics and blood screening businesses and substantially...